The label-free detection of one of the cardiac biomarkers, myoglobin, using a photonic-crystal-based biosensor in a total-internal-reflection configuration (PC-TIR) is presented in this paper. The PC-TIR sensor possesses a unique open optical microcavity that allows for several key advantages in biomolecular assays. In contrast to a conventional closed microcavity, the open configuration allows easy functionalization of the sensing surface for rapid biomolecular binding assays. Moreover, the properties of PC structures make it easy to be designed and engineered for operating at any optical wavelength. Through fine design of the photonic crystal structure, biochemical modification of the sensor surface, and integration with a microfluidic system, we have demonstrated that the detection sensitivity of the sensor for myoglobin has reached the clinically significant concentration range, enabling potential usage of this biosensor for diagnosis of acute myocardial infarction. The real-time response of the sensor to the myoglobin binding may potentially provide point-of-care monitoring of patients and treatment effects. 1. Introduction The diagnosis of cardiac disorders becomes more and more important with the incidence of acute myocardial infarction (AMI) commanding one of the highest mortality rates in the US and around the world [1]. Each year, approximately 635,000 people suffer from AMI [2], among whom it is estimated that 50% will die within the first hour of symptoms [3]. For this reason, many studies have been conducted to shorten the time required to diagnose AMI [2–5]. Given the complex pathophysiology of heart disease, interests have intensified in plasma biochemical markers to predict susceptibility and aid in patient management. After an AMI has occurred, cardiac biomarkers, such as myoglobin, troponin I (cTnI), troponin T (cTnT), and creatine kinase (CK-MB), are released into the bloodstream [3, 4, 6]. In 2000, the World Health Organization set a standard allowing physicians to use the troponins and CK-MB levels, in addition to ECG and the patients’ history, to diagnose AMI [7]. Although the serum detection of these biomarkers aids in an accurate diagnosis, it is usually time consuming due to the laborious lab techniques and logistics of sample transportation to a central lab. Both the turnaround time for laboratory diagnosis and the elapsed time for cTnI or CK-MB biomarkers to be released into the body (up to 3 hours for cTnI and 6 hours for CK-MB after an AMI) [3] may lead to a delay in prime-time treatment or hospitalization of a patient with
References
[1]
W. H. W. Tang, G. S. Francis, D. A. Morrow et al., “National academy of clinical biochemistry laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure,” Circulation, vol. 116, no. 5, pp. E99–E109, 2007.
[2]
V. L. Roger, A. S. Go, D. M. Lloyd-Jones, et al., “Heart disease and stroke statistics—2012 update: a report from the American Heart Association,” Circulation, vol. 125, no. 1, pp. e2–e220, 2012.
[3]
A. L. Straface, J. H. Myers, H. J. Kirchick, and K. E. Blick, “A rapid point-of-care cardiac marker testing strategy facilitates the rapid diagnosis and management of chest pain patients in the emergency department,” American Journal of Clinical Pathology, vol. 129, no. 5, pp. 788–795, 2008.
[4]
J. McCord, R. M. Nowak, P. A. McCullough et al., “Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I,” Circulation, vol. 104, no. 13, pp. 1483–1488, 2001.
[5]
S. P. J. Macdonald and Y. Nagree, “Rapid risk stratification in suspected acute coronary syndrome using serial multiple cardiac biomarkers: a pilot study,” Emergency Medicine Australasia, vol. 20, no. 5, pp. 403–409, 2008.
[6]
S. M. Sallach, R. Nowak, M. P. Hudson et al., “A change in serum myoglobin to detect acute myocardial infarction in patients with normal troponin I levels,” American Journal of Cardiology, vol. 94, no. 7, pp. 864–867, 2004.
[7]
J. S. Alpert, K. Thygesen, E. Antman, and J. P. Bassand, “Myocardial infarction redefined—a consensus document of the joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction,” Journal of the American College of Cardiology, vol. 36, no. 3, pp. 959–969, 2000.
[8]
G. X. Brogan, S. Friedman, C. McCuskey et al., “Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the emergency department,” Annals of Emergency Medicine, vol. 24, no. 4, pp. 665–671, 1994.
[9]
F. S. Apple, R. H. Christenson, R. Valdes et al., “Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction,” Clinical Chemistry, vol. 45, no. 2, pp. 199–205, 1999.
[10]
U. Friess and M. Stark, “Cardiac markers: a clear cause for point-of-care testing,” Analytical and Bioanalytical Chemistry, vol. 393, no. 5, pp. 1453–1462, 2009.
[11]
R. H. Christenson and H. M. E. Azzazy, “Cardiac point of care testing: a focused review of current National Academy of Clinical Biochemistry guidelines and measurement platforms,” Clinical Biochemistry, vol. 42, no. 3, pp. 150–157, 2009.
[12]
F. Darain, P. Yager, K. L. Gan, and S. C. Tjin, “On-chip detection of myoglobin based on fluorescence,” Biosensors and Bioelectronics, vol. 24, no. 6, pp. 1744–1750, 2009.
[13]
R. Kurita, Y. Yokota, Y. Sato, F. Mizutani, and O. Niwa, “On-chip enzyme immunoassay of a cardiac marker using a microfluidic device combined with a portable surface plasmon resonance system,” Analytical Chemistry, vol. 78, no. 15, pp. 5525–5531, 2006.
[14]
Y. Arntz, J. D. Seelig, H. P. Lang et al., “Label-free protein assay based on a nanomechanical cantilever array,” Nanotechnology, vol. 14, no. 1, pp. 86–90, 2003.
[15]
T. W. Lin, P. J. Hsieha, C. L. Linc, et al., “Label-free detection of protein-protein interactions using a calmodulin-modified nanowire transistor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 3, pp. 1047–1052, 2010.
[16]
K. W. Wee, G. Y. Kang, J. Park et al., “Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers,” Biosensors and Bioelectronics, vol. 20, no. 10, pp. 1932–1938, 2005.
[17]
A. Kooser, K. Manygoats, M. P. Eastman, and T. L. Porter, “Investigation of the antigen antibody reaction between anti-bovine serum albumin (a-BSA) and bovine serum albumin (BSA) using piezoresistive microcantilever based sensors,” Biosensors and Bioelectronics, vol. 19, no. 5, pp. 503–508, 2003.
[18]
S. Chakravarty, Y. Zoua, W. C. Laia, et al., “Slow light engineering for high Q high sensitivity photonic crystal microcavity biosensors in silicon,” Biosensors & Bioelectronics, vol. 38, no. 1, pp. 170–176, 2012.
[19]
W. C. Lai, S. Chakravarty, Y. Zou, et al., “Silicon photonic crystal microcavity biosensors for label free highly sensitive and specific lung cancer detection,” IEEE Photonics Conference, vol. 2012, pp. 443–444, 2012.
[20]
S. Pal, E. Guillermain, R. Sriram, B. L. Miller, and P. M. Fauchet, “Silicon photonic crystal nanocavity-coupled waveguides for error-corrected optical biosensing,” Biosensors & Bioelectronics, vol. 26, no. 10, pp. 4024–4031, 2011.
[21]
R. Sriram, E. Baker, P. M. Fauchet, et al., “Two dimensional photonic crystal biosensors as a platform for label-free sensing of biomolecules,” International Society For Optics and Photonics, vol. 8570, 2013.
[22]
I. L. Lee, X. Luo, and J. Huang, “Detection of cardiac biomarkers using single polyaniline nanowire-base conductometric biosensors,” Biosensors, vol. 2, pp. 205–220, 2012.
[23]
C. Van？ura, J. Lichtenberg, A. Hierlemann, and F. Josse, “Characterization of magnetically actuated resonant cantilevers in viscous fluids,” Applied Physics Letters, vol. 87, no. 16, Article ID 162510, pp. 1–3, 2005.
[24]
J. Y. G. Ye, T. B. Norris, and J. Baker, “Patent issued,” Patent No. 7, 639, 632, 2009.
[25]
B. L. Zhang, S. Dallo, R. Peterson, et al., “Detection of anthrax lef with DNA-based photonic crystal sensors,” Journal of Biomedical Optics, vol. 16, no. 12, 2011.
[26]
S. F. Dallo, B. Zhang, J. Denno, et al., “Association of acinetobacter baumannii EF-Tu with cell surface, outer membrane vesicles, and fibronectin,” Scientific World Journal, vol. 2012, Article ID 128705, 2012.
[27]
Y. Guo, C. Divin, A. Myc et al., “Sensitive molecular binding assay using a photonic crystal structure in total internal reflection,” Optics Express, vol. 16, no. 16, pp. 11741–11749, 2008.
[28]
Y. Guo, J. Y. Ye, C. Divin et al., “Real-time biomolecular binding detection using a sensitive photonic crystal biosensor,” Analytical Chemistry, vol. 82, no. 12, pp. 5211–5218, 2010.
[29]
S. Flink, F. C. J. M. Van Veggel, and D. N. Reinhoudt, “Functionalization of self-assembled monolayers on glass and oxidized silicon wafers by surface reactions,” Journal of Physical Organic Chemistry, vol. 14, no. 7, pp. 407–415, 2001.
[30]
R. H. Aebersold, D. B. Teplow, L. E. Hood, and S. B. H. Kent, “Electroblotting onto activated glass. High efficiency preparation of proteins from analytical sodium dodecyl sulfate-polyacrylamide gels for direct sequence analysis,” The Journal of Biological Chemistry, vol. 261, no. 9, pp. 4229–4238, 1986.
[31]
S. H. Jung, J. W. Jung, I. B. Suh et al., “Analysis of C-reactive protein on amide-linked N-hydroxysuccinimide-dextran arrays with a spectral surface plasmon resonance biosensor for serodiagnosis,” Analytical Chemistry, vol. 79, no. 15, pp. 5703–5710, 2007.
[32]
S. M. S. Diagnostics, ADVIA Centaur Assay Mannual Myoglobin Review E, 2004.
[33]
S. M. S. Diagnostics, ADVIA Centaur Mannual CKMB, 111803. REView G, 2003.
[34]
M. A. Cooper and D. H. Williams, “Kinetic analysis of antibody-antigen interactions at a supported lipid monolayer,” Analytical Biochemistry, vol. 276, no. 1, pp. 36–47, 1999.
[35]
T. M. A. D. Myszka, Kinetic & Affinity Characterization—Monocolonal Antibodies, http://www.attana.com/wp-content/uploads/2013/01/AE01-03-KineticaAffinity_MAbs.pdf Attana, Editor, 2002.
[36]
M. P. Hudson, R. H. Christenson, L. K. Newby, A. L. Kaplan, and E. M. Ohman, “Cardiac markers: point of care testing,” Clinica Chimica Acta, vol. 284, no. 2, pp. 223–237, 1999.
